Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras
Journal of Clinical Oncology · 12.11.2026
DOI: 10.1200/jco-26-00418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 12.11.2026. Verfasst von Aislinn Macklin-Doherty und 21 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research Biomedical Research Centre, London, United Kingdom. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Purpose
Subsequent primary malignancies (SPMs) are the leading cause of long-term treatment-related mortality in Hodgkin lymphoma (HL). Although treatments have evolved substantially over recent decades, few studies have demonstrated reductions in SPM risks following modern treatments, nor how such changes should inform survivorship care and screening. We analyzed SPM risks in a large female cohort of childhood and adult patients with HL treated over a 60-year period. Materials and Methods This population-based cohort study included 7,428 women diagnosed with HL before age 36 years in England and Wales from 1954 to 2010, with follow-up through 2018. SPMs were ascertained via national cancer registry linkages. Standardized incidence ratios (SIRs), absolute excess risks, and multivariable models were used to assess temporal trends and associations with treatment.
Results
During a median follow-up of 20.2 years, 1,200 women developed 1,467 invasive cancers (SIR, 3.3 [95% CI, 3.1 to 3.5]), most commonly breast, lung, and thyroid cancers. Solid tumor risks were the highest following radiotherapy, with a strong dose-dependent response. Alkylator use with radiotherapy was associated with reduced risks of breast cancer but increased risks of GI cancers. Solid cancer risks decreased by 25% between treatment periods 1954-1989 and 2000-2010. The decrease was attenuated and nonsignificant after adjustment for radiotherapy but not affected by adjustment for chemotherapy. No decline was observed for hematologic malignancies. Cumulative incidence of SPMs reached 36% at 50 years.
Conclusion
Female patients treated in more recent eras have a substantially lower long-term risk of solid SPMs largely attributable to the reduced use, dose, and improvement in radiotherapy. Nevertheless, persistently elevated risks remained beyond 50 years of follow-up, particularly for lung and breast cancer, underscoring the need for lifelong surveillance and targeted screening of survivors.
Autor:innen und Institutionen
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research Biomedical Research Centre, London, United Kingdom.
- University Hospital Southampton NHS Foundation Trust, Hampshire, United Kingdom.
- Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom.
- Imperial College London, London, United Kingdom.
- University Hospital of North Midlands & School of Medicine, Keele University, Staffordshire, United Kingdom.
- Guy's and St Thomas' NHS Trust, London, United Kingdom.
ORCID-Profile: Aislinn Macklin-Doherty, David Cunningham, Ian Chau, Mark Bower, Christopher P Fox, John G Gribben, Peter Hoskin, John Radford, Anjali Zarkar, Michael E Jones
Zitieren
APA
Macklin-Doherty, A., Cunningham, D., Chau, I., Bates, A., Benstead, K., Bower, M., Brunt, M., Fields, P., Follows, G., Fox, C. P., Frew, J., Gribben, J. G., Hoskin, P., Irwin, C., Lowry, L., Radford, J., Syndikus, I., Zarkar, A., Thomas, E., …, & Swerdlow, A. J. (2026). Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00418
Vancouver
Macklin-Doherty A, Cunningham D, Chau I, Bates A, Benstead K, Bower M, et al. Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00418
BibTeX
@article{MacklinDoherty2026,
author = {Macklin-Doherty, Aislinn and Cunningham, David and Chau, Ian and Bates, Andrew and Benstead, Kim and Bower, Mark and Brunt, Murray and Fields, Paul and Follows, George and Fox, Christopher P and Frew, John and Gribben, John G and Hoskin, Peter and Irwin, Clive and Lowry, Lisa and Radford, John and Syndikus, Isabel and Zarkar, Anjali and Thomas, Emma and Berrington de Gonzalez, Amy and Jones, Michael E and Swerdlow, Anthony J},
title = {Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00418}
}
EUVIMED